GMED * Stock Overview
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Globus Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$990.00 |
| 52 Week High | US$990.00 |
| 52 Week Low | US$972.01 |
| Beta | 1.11 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -30.51% |
| 5 Year Change | 18.51% |
| Change since IPO | 6.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| GMED * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | n/a | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how GMED * performed against the MX Medical Equipment industry.
Return vs Market: Insufficient data to determine how GMED * performed against the MX Market.
Price Volatility
| GMED * volatility | |
|---|---|
| GMED * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: GMED * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GMED *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 5,000 | Dan Scavilla | www.globusmedical.com |
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants.
Globus Medical, Inc. Fundamentals Summary
| GMED * fundamental statistics | |
|---|---|
| Market cap | Mex$146.71b |
| Earnings (TTM) | Mex$1.12b |
| Revenue (TTM) | Mex$31.86b |
131.2x
P/E Ratio4.6x
P/S RatioIs GMED * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMED * income statement (TTM) | |
|---|---|
| Revenue | US$1.90b |
| Cost of Revenue | US$593.51m |
| Gross Profit | US$1.30b |
| Other Expenses | US$1.24b |
| Earnings | US$66.63m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.49 |
| Gross Margin | 68.74% |
| Net Profit Margin | 3.51% |
| Debt/Equity Ratio | 10.8% |
How did GMED * perform over the long term?
See historical performance and comparison